Skip to main content

LIVE

CMMB

Chemomab Therapeutics Ltd.

CMMB

NASDAQ·Healthcare·Biotechnology·Mkt cap $16.7M

$2.71

-4.24%

P/E

-5.04

Mkt Cap

$16.7M

52-Wk Range

$1.35–$3.58

52-Week Range

$1.35 - $3.58

P/E

-5.04

Fwd P/E

-135.50

Beta

0.66

Div Yield

0.00%

Avg Vol

118.1K

Shares Out

6.2M

Mkt Cap

$16.7M

Price action

Price chart

Down 12.3% over the trailing year

Total returns

Price performance

Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.

Why we rate it this way

The thesis at a glance

Bull and bear case · plain-English context across the five lenses we evaluate.

Bull Case

4 reasons

  • Proprietary CCL24 inhibition technology targeting unmet medical needs
  • Experienced clinical-stage biotech management team with deep immunology expertise
  • First-mover advantage in CCL24-targeted therapies for PSC and SSc
  • Focused pipeline strategy enabling concentrated resource allocation and rapid development

Bear Case

1 risk

  • Low volatility (beta 0.7).

Growth

Stable outlook

Clinical trial progression and regulatory milestones for CM-101

Value

Deep value opportunity - significant discount to Biotech & Therapeutics peers

Momentum

Hot

+53.1% over 3m

Quality

Loss-making

Solid business

Dividend

None

No dividend

Earnings track record

Recent earnings results

AI-summarized recap of last quarter, plus the surprise on every print.

Next: Nov 6, 2026

Q3 26 RECAP

AUG 19, 2026

Reported EPS of -$0.27 vs -$0.15 consensus (-80.0% surprise).

EPS miss

EPS surprise · last 4Q

0 of 1 beats

Estimate

Actual

Q3 26

-80.0%

Revenue trend · last 8Q

Q3 24

Q4 24

Q1 25

Q2 25

Q3 25

Q4 25

Q1 26

Q2 26

$0

$0

$0

$0

$0

$0

$0

$0

Margins · last 8Q

No margin history available.

Wall Street consensus

Analyst coverage

Live ratings and price targets aggregated across covering analysts.

vs Industry

How CMMB stacks vs Biotechnology

Stock metrics vs industry averages. Green = better than industry.

Industry comparison data unavailable for this stock.